Therapeutic effect of granulocyte and monocyte adsorption column (Adacolumn) for refractory skin diseases

Therapeutic effect of granulocyte and monocyte adsorption column (Adacolumn) for refractory skin diseases - Therapeutic effect of granulocyte and monocyte adsorption column (Adacolumn) for refractory skin diseases

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021070

Enrollment

Registered

2016-02-17

Start date

2015-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory keratosis (psoriasis vulgaris, psoriasis arthropica), neutrophilic dermatosis (pustular psoriasis, palmoplantar pustulosis, Behcet disease, Sweet disease, gangrene pyoderma, erythema elevatum diutinum) , vasculitis syndrome (nodular arteritis, cutaneous allergic vasculitis, Schonlein-Henoch purpura, Wegener&#39

Interventions

Once to twice a week, we treat the target patients with granulocyte and monocyte adsorption column, as a rule a total of 5 times.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inflammatory keratosis (psoriasis vulgaris, psoriasis arthropathica), neutrophilic dermatosis (pustular psoriasis, palmoplantar pustulosis, Behcet disease, Sweet disease, gangrene pyoderma, erythema elevatum diutinum) , vasculitis syndrome (nodular arteritis, cutaneous allergic vasculitis, Schonlein-Henoch purpura, Wegener granulomatosis), eosinophilic disease (bullous pemphigoid, hypereosinophilic syndrome, good eosinophilic pustular folliculitis, eosinophilic cellulitis, eosinophilic fasciitis, atopic dermatitis)

Exclusion criteria

Exclusion criteria: no paticular

Design outcomes

Primary

Measure	Time frame
cutaneous findings pre treatment and after treatment (5 times or 10 times)	—

Secondary

Measure	Time frame
laboratory assessmentperipheral blood, general biochemical examination, MAC-1, leukocyte, T-reg, HMGB-1, bone marrow-derived lymphocytes, inflammatory chemical mediators, cytokines (interleukin, CTACK, GROa, LIF, MCP-3, M-CSF , MIF, MIG, b-NGF, SCF, SCGF-b, SDF-1a, TNF-a, TNF-b, TRAIL, HGF, INF, GM-CSF)) certain symptom (pre and after treatment)	—

Countries

Japan

Contacts

Public ContactMasanao Sakanoue

Kagoshima University dermatology

sakanoue@m3.kufm.kagoshima-u.ac.jp099-275-5388

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026